Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.54 |
| ▸ | NPY1R | P25929 | 6/20 | 0.54 |
| ▸ | NPY2R | P49146 | 5/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.54 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30433385 | 0.91 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30798852 | 0.87 | F2 (0.49) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL9555600 | 0.86 | ACE (0.59) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL9555596 | 0.86 | ACE (0.59) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30037959 | 0.84 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29868753 | 0.83 | LNPEP (0.55) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29014899 | 0.83 | NPY4R (0.53) | NPY4RNPY1RNPY2R | |
| SCHEMBL29014895 | 0.83 | NPY4R (0.53) | NPY4RNPY1RNPY2R | |
| SCHEMBL31114987 | 0.83 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL11043731 | 0.83 | OPRK1 (0.53) | NPY4RNPY1RNPY2RNPY5RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116984-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | NATIONAL SCIENCE FOUNDATION | 2024-04-11 | — | — | US | disclosed |
| US-20230399361-A1 | MACROCYCLIC PEPTIDES | UNIVERSITY OF NOTRE DAME DU LAC | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116984-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | PRNP, MAPT, APP | NPY4R 2172/4885NPY1R 2265/4885NPY2R 2240/4885 |
| US-20230399361-A1 | MACROCYCLIC PEPTIDES | APP, MAPT, NEFM | NPY4R 1577/4885NPY1R 1249/4885NPY2R 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.